Wells Pharma
Wells Pharma is a Houston-based FDA-registered 503B outsourcing facility that manufactures and distributes ready-to-use sterile compounded medications to hospitals and ambulatory surgery centers across 48 U.S. states.
- Company typePrivate
- Founded2020
- HeadquartersHouston, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Wells Pharma does
Wells Pharma is an FDA-registered 503B outsourcing facility founded in 2020 and headquartered in the Texas Medical Center corridor of Houston, Texas. The company manufactures and distributes ready-to-use sterile compounded medications to hospitals and ambulatory surgery centers across 48 U.S. states. Its portfolio of 60+ products is organized into OR syringes, antibiotics (ceFAZolin, Vancomycin), pain/PCA preparations (Fentanyl, Morphine, Ketamine, Midazolam), epidural and nerve block products (Ropivacaine, Lidocaine), standard IV admixtures, and selected non-sterile products, with drug-shortage medications positioned as a strategic category. Manufacturing occurs in ISO-classified cleanroom infrastructure (currently 10 operational ISO-5 vertical laminar flow hoods, two ISO 7 cleanrooms, and one ISO 8 API dispensing suite, with 14 additional hoods being commissioned) operating under cGMP and USP <797>, <788>, and <85> standards, with DEA registration permitting compounding of Schedule II controlled substances such as Fentanyl and Morphine.
The business model is B2B direct sales of compounded sterile medications through a dedicated enterprise field sales team of regional AVPs organized by territory and an online ordering portal for healthcare providers. Pricing is quote-based and not publicly disclosed. Wells Pharma is differentiated primarily via its regulatory status, quality release testing on 100% of batches, 48-hour standard lead times, and a stated "5Cs" framework (Confidence in Quality, Customer Service, Comprehensive Portfolio, Consistent Supply, Competitive Value). The company is privately held and operating; ownership is not publicly disclosed and no parent company, subsidiaries, or external funding rounds are identified in the available sources. Leadership includes President and CFO Andy Corbin (previously led a 42,000 sq ft 503B build-out), VP of Quality Carissa Imrecke, SVP of Sales and Marketing Stan Pflueger (credited with 213% average annual revenue growth since 2021), and VP of Sales David Koch.
Wells Pharma firmographics
Firmographics- Name
- Wells Pharma
- Legal name
- Wells Pharma
- Website
- https://wellspharmatx.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Wells Pharma is a Houston-based FDA-registered 503B outsourcing facility that manufactures and distributes ready-to-use sterile compounded medications to hospitals and ambulatory surgery centers across 48 U.S. states.
- Ownership category
- akta.pro rank
Wells Pharma industry classification
Industry- Product category
- 503B Compounded Sterile Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (42421), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Compounding Pharmacies (Sterile/Non-Sterile) (HLAFALAE)
- akta.pro secondary industry
- Controlled Substances & Compliance-Focused Pharmaceutical Distributors (HLAIAJAN)
Keywords
Where Wells Pharma is headquartered
LocationHeadquarters
- HQ city
- Houston
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Wells Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Personnel, Supply Chain, Infrastructure, Technology or R&D, Marketing or Sales
Revenue model
- Compounded Sterile Medications Sales: B2B sales of FDA-registered 503B compounded sterile medications to hospitals and surgery centers. Products include ready-to-use prefilled syringes, IV admixtures, sterile admixtures, and drug-shortage medications. Revenue generated through direct product sales with order fulfillment through online portal and sales team coordination.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels5 records
Wells Pharma product offering
Product offeringCore offering
Wells Pharma operates an FDA-registered 503B outsourcing facility that manufactures and sells ready-to-use sterile compounded medications, including prefilled syringes, IV admixtures, antibiotics (ceFAZolin, Vancomycin), anesthesia agents, neuromuscular blockers, vasopressors, pain/PCA preparations, epidural and nerve block products, and drug-shortage medications, primarily to U.S. hospitals and ambulatory surgery centers. All products are cGMP-compliant, produced under USP <797>, <788>, and <85> standards, sterility and potency tested, and shipped to 48 states with most orders fulfilled within 48 hours.
Product overview
Wells Pharma is an FDA-registered 503B outsourcing facility providing a portfolio of ready-to-use sterile compounded medications to hospitals and surgery centers nationwide. The product portfolio includes: OR Syringes (anesthetic agents including Fentanyl, Ketamine, Midazolam; neuromuscular blockers including Rocuronium, Succinylcholine; vasopressors including Phenylephrine, Ephedrine; anticholinergics including Atropine, Glycopyrrolate; reversal agents including Neostigmine; beta-blockers including Esmolol; and local anesthetics including Lidocaine); Antibiotics (ceFAZolin and Vancomycin in multiple strengths and formulations); Pain/PCA Products (Fentanyl combinations with Ropivacaine, Morphine prefilled syringes, Ketamine, and Midazolam); Epidural & Nerve Block Preparations (Ropivacaine 0.2% and combination products); IV Admixtures (antibiotic bags in 0.9% Sodium Chloride); and Non-Sterile Products (Indomethacin suppository). Additional offerings include Pre-Filled Arrow Pain Pumps and Drug Shortage Medications. All sterile products are manufactured under cGMP compliance with sterility, endotoxin, and potency testing before release.
Differentiator
Problem solved
Functional benefit
Products and services
- OR Syringes Portfolio Ready-to-use prefilled syringes designed to support operating room efficiency by reducing on-site preparation steps; includes anesthesia agents, neuromuscular blockers, vasopressors, reversal agents, anticholinergics, beta-blockers, and local anesthetics with sterility, particulate, and potency testing.
- Antibiotic Preparations (ceFAZolin and Vancomycin) Sterile antibiotic preparations of ceFAZolin (1gm, 2gm, 3gm) and Vancomycin (1gm–2gm) in 0.9% Sodium Chloride bags and Sterile Water for Injection syringes, designed to support antimicrobial stewardship initiatives and standardized treatment protocols in hospitals.
- Pain / PCA Preparations (Fentanyl, Ketamine, Midazolam, Morphine, Lidocaine) Sterile prefilled syringes and IV bags for Patient-Controlled Analgesia and pain management including opioid analgesics (Fentanyl 50mcg–2,500mcg, Morphine 2mg), benzodiazepines (Midazolam 50mg/50mL–100mg/100mL), anesthetics (Ketamine 50mg, 100mg), and local anesthetics (Lidocaine 60mg, 100mg).
- Epidural & Nerve Block Preparations Sterile prefilled syringes including Ropivacaine 0.2% in 0.9% Sodium Chloride, used for regional anesthesia and epidural procedures, supporting anesthesia protocols requiring precision and consistency.
- IV Admixtures and Standard Services Sterile IV preparations including antibiotic admixtures (ceFAZolin, Vancomycin), analgesic combinations, hypertonic Dextrose 50% in Sterile Water for Injection, and other sterile-to-sterile formulations provided in 0.9% Sodium Chloride bags to reduce pharmacy compounding burden.
- Pre-Filled Arrow Pain Pumps Ready-to-use pre-filled pain management infusion pumps designed for Patient-Controlled Analgesia (PCA) delivery systems, supporting postoperative pain management protocols in hospitals and surgery centers.
- Non-Sterile Products (Indomethacin Suppository) Non-sterile NSAID preparation of Indomethacin 100mg suppository for anti-inflammatory and analgesic therapy in conditions requiring rectal administration.
- Drug Shortage Medications Supply Critical medications supplied during national drug shortages and supply disruptions, including proactive inventory planning and scalable production to help hospitals and surgery centers maintain continuity of care.
Quantifiable outcome
- 100% batches evaluated for sterility, particulate levels, and potency
- +1 more outcomes
Companies that use Wells Pharma
Customer profileNamed customers2 records
Segments2 records
Ideal customer profiles2 records
Wells Pharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Wells Pharma partnerships and signals
Strategic signalScale indicators8 records
Recent moves7 records
Expansion highlights5 records
Wells Pharma competitors and assessment
Company assessmentDirect peers
- QuVa Pharma: QuVa Pharma is an FDA-registered 503B outsourcing facility producing ready-to-use sterile compounded preparations for hospitals. It is one of the closest direct competitors to Wells Pharma in the hospital 503B sterile admixture and prefilled syringe market.
- SCA Pharma: SCA Pharma is one of the largest FDA-registered 503B outsourcing facilities producing sterile admixtures and prefilled syringes for hospitals and surgery centers. It is explicitly named as a key Wells Pharma peer and competes head-to-head across OR syringe, pain management, and antibiotic product lines.
- Nephron Pharmaceuticals Corporation: Nephron operates an FDA-registered 503B outsourcing division alongside generic manufacturing, supplying sterile prefilled syringes and IV bags to hospitals. Wells Pharma explicitly identifies Nephron as a key 503B peer competing in the same nationwide hospital market.
- Athenex: Athenex operated a 503B outsourcing facility producing sterile compounded medications for hospitals. Wells Pharma lists Athenex as a key 503B peer; Athenex's recent strategic restructuring makes it a comparable but distressed reference point for facility-level economics.
- Olympia Pharmacy: Olympia Pharmacy operates an FDA-registered 503B outsourcing facility providing sterile compounded preparations to hospitals and surgery centers. It is explicitly listed by Wells Pharma as a key market peer, with overlapping OR syringe and perioperative product lines.
- Central Admixture Pharmacy Services (CAPS): CAPS is one of the largest 503B outsourcing networks, providing sterile admixture and prefilled syringe services to hospital systems nationwide. It is a direct competitor to Wells Pharma in the hospital outsourced sterile compounding category.
- Leiters Health: Leiters is an FDA-registered 503B outsourcing facility producing ready-to-administer sterile preparations, including ophthalmic and anesthesia products. It is comparable to Wells Pharma as a hospital-focused 503B outsourcer with cGMP operations.
- Fagron Compounding Pharmacies: Fagron operates compounding pharmacy operations serving hospitals and clinics, including sterile and non-sterile preparations. It is explicitly named by Wells Pharma as a key peer and overlaps on hospital custom-compounded product offerings.
Emerging players
- STAQ Pharma: STAQ Pharma is an FDA-registered 503B outsourcing facility producing sterile injectable preparations for hospitals. It is a smaller, emerging 503B competitor that overlaps with Wells Pharma's hospital customer base and ready-to-use product positioning.
Broad incumbents
- ICU Medical (PharmaMedium): ICU Medical acquired Pharmedium Services, one of the largest 503B outsourcing operations in the US. As a broad medical device and infusion therapy incumbent, ICU Medical represents a scaled 503B competitor and potential strategic acquirer for Wells Pharma.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Wells Pharma social profiles
Digital presenceWells Pharma compliance and trust
Trust signalCompliance6 records
Wells Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Wells Pharma leadership team
Management profileNumber of profiles
Profiles13 records
Wells Pharma funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Wells Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Wells Pharma
What does Wells Pharma do?
Wells Pharma operates an FDA-registered 503B outsourcing facility that manufactures and sells ready-to-use sterile compounded medications, including prefilled syringes, IV admixtures, antibiotics (ceFAZolin, Vancomycin), anesthesia agents, neuromuscular blockers, vasopressors, pain/PCA preparations, epidural and nerve block products, and drug-shortage medications, primarily to U.S. hospitals and ambulatory surgery centers. All products are cGMP-compliant, produced under USP <797>, <788>, and <85> standards, sterility and potency tested, and shipped to 48 states with most orders fulfilled within 48 hours.
Is Wells Pharma a public or private company?
Wells Pharma is a private company. It is classified as unknown and is currently operating.
When was Wells Pharma founded?
Wells Pharma was founded in 2020. It employs 51 to 100 people.
Where is Wells Pharma based?
Wells Pharma is headquartered in Houston, United States, in the North America region.
How does Wells Pharma make money?
One revenue line is on record: compounded Sterile Medications Sales.
Who are Wells Pharma's main competitors?
Direct peers on record are QuVa Pharma, SCA Pharma, Nephron Pharmaceuticals Corporation, Athenex, Olympia Pharmacy, Central Admixture Pharmacy Services (CAPS), Leiters Health and Fagron Compounding Pharmacies. STAQ Pharma is listed as an emerging player. ICU Medical (PharmaMedium) is listed as a broad incumbent.
Does Wells Pharma have an API?
No public API is recorded for Wells Pharma.
What industry is Wells Pharma in?
Wells Pharma's product category is 503B Compounded Sterile Pharmaceuticals. Its primary akta.pro industry code is HLAFALAE, Compounding Pharmacies (Sterile/Non-Sterile), with a secondary code of HLAIAJAN, Controlled Substances & Compliance-Focused Pharmaceutical Distributors. Its NAICS code is 325412 and its SIC code is 2834.